



# COntinuous Multi-parametric and Multi-layered analysis Of Diabetes TYpe 1 & 2

**Oliver Keller<sup>1</sup>, Olivier Marchesini<sup>2</sup>, Przemyslaw Kardas<sup>3</sup>,  
Serban-George Puricel<sup>4</sup>, Stefano Bromuri<sup>5</sup>**

<sup>1</sup>Deutsches Forschungszentrum für Künstliche Intelligenz GmbH, Saarbrücken, Germany, <sup>2</sup>Portavita B.V., Amsterdam, The Netherlands, <sup>3</sup>Medical University of Lodz, Poland, <sup>4</sup>Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, <sup>5</sup>Haute Ecole Spécialisée de Suisse Occidentale

The Commodity12 project is partially funded by the Eu.

Collaborative Project

**7th Framework Programme**

Priority FP7-ICT-2011-7

Information Society Technologies

Proposal No 287841

<http://www.commodity12.eu/>

  
Advanced Technologies & Treatments for Diabetes

**7<sup>th</sup> INTERNATIONAL CONFERENCE  
ON ADVANCED TECHNOLOGIES &  
TREATMENTS FOR DIABETES**  
**FEBRUARY 5-8, 2014  
VIENNA, AUSTRIA**

**Workshop**

**“7th Framework Program–funded  
eHealth systems for diabetes”**


**ATTD 2014, Vienna, February 5, 2014**

# Plan of the presentation




- Ecosystem Commodity12
- The impact on the treatment chain
- The impact on the medical innovation chain
- Technical challenges of Commodity12
- Medical characteristics of the Commodity12
- Commodity12 validation in clinical trials

# Ecosystem Commodity12




Logical Structure for Dissemination Version 1.0

# Impact on the treatment chain



# Impact on medical innovation



- **Patient acceptance** of the body sensors
- Validation and acceptance by the users of **Artificial Intelligence**
- **Compliance** of the platform **with European laws** (Medical Devices Directive)
- **Usability** of the different modules
- **Internal compatibility** and **external interoperability** of the platform
- **Sustainability** of the platform

# Medical characteristics of COMMODITY<sub>12</sub> system



- Helps healthcare professionals in **analysing medical data**
- **Empowers** the patients in **self-management** of their disease
- Designed for both **DM1** and **DM2** patients
- Takes care of **cardiovascular comorbidities**

# COMMODITY<sub>12</sub> system algorithm



## Medical knowledge based on:

- Current guidelines
- Results of the focus studies
- Analysis of large databanks

Along the system use, **new knowledge will be accumulated!**

- Analysis of clinical outcomes
- Lifestyle & patient history
- Genetic factors



# Parameters to be used by COMMODITY<sub>12</sub> system

## Parameters of the **glycemic control**:

- fasting glucose – mean, % of time within range
- HbA1c
- hypoglycemic events



## Parameters allowing for **calculation of CV risk**:

- physiological parameters
- lifestyle & patient history
- genetic factors

## Other parameters

- Patient adherence



# Aims of COMMODITY<sub>12</sub> clinical trials



- To assess the **concept and performance of C12 system** in real life conditions by comparison of e-health and conventional methods of diabetes-related data management
- To test the **results of the COMMODITY12 Project** by performing rigorous prototype validation of C12 system with real patients.
- To lay a **foundation for future commercialization** of C12 system

**Telemedical outpatient monitoring and management by  
COntinuous Multi-parametric and Multi-layered analysis  
Of TYpe 1 diabetes mellitus (COMMODITY 1): An open  
randomized controlled pilot study on behalf of the  
COMMODITY 12 Investigators**

Dr. med. Serban-George Puricel  
ATTD 2014  
Vienna

## Patient with a diagnosis of Diabetes Mellitus Type 1

>18 years  
Speaks French  
Written informed consent  
Willing to participate in follow-up  
No major psychosocial impairment  
Pregnancy

Single center, parallel group, open  
label, randomized controlled trial



**1:1 Randomization per sealed envelope**

**Standard Care**  
**N=20**

*3 months follow-up*

**PHS Care**  
**N=20**

PHS = Personal Health System

**1° end point:** Whole trial feasibility and system  
operability

**2° end points:** HbA1c, plasma glucose, hypo- and hyperglycemic episodes,  
arterial blood pressure, weight, number of clinic visits, health care

costs

## PHS Care

**Clinic visit 1**

Baseline

Height, weight, blood pressure, pulse, abdominal girth, HbA1c, total cholesterol, LDL, HDL, triglycerides, creatinine, urea, sodium, potassium, urinary albumins

6x/day plasma glucose

2x/week: blood pressure

2x/week: Weight

CGM during 4 days 1x/month

2x/week (1x at day and 1x at night): heart and respiratory rate

1 Month


2 Months

**Clinic visit 2**

3 Months

Height, weight, blood pressure, pulse, abdominal girth, HbA1c, total cholesterol, LDL, HDL, triglycerides, creatinine, urea, sodium, potassium, urinary albumins, genetic analysis

**Study completion**



## Improve Glycemic control

**Alerts for Hypoglycemia**

**Alerts for Hyperglycemia**

**Alerts for HbA1c target**

Alerts based on the 2014 ADA Position Statement – Standards of Medical Care in Diabetes

## Retrospective Analysis of CGM Data

**Improve Prediction of Hypo-  
/Hyperglycemia in individual  
patients**


**Improve understanding of  
Hypo-/Hyperglycemia**

# COMMODITY<sub>2</sub> trial in DM2 patients

## Inclusion criteria (selected)



- Diagnosis: DM2
- Phase of the treatment: maintenance therapy
- Age: 18-65
- Ability to use the cell phone and the sensors




# COMMODITY<sub>2</sub> trial in DM<sub>2</sub> patients

## General design




Trial design: randomized controlled minifeasibility trial





# COMMODITY<sub>2</sub> trial in DM<sub>2</sub> patients

## Parameters assessed



- physiological parameters
- genetic factors
- patient history

- glycemic control parameters
- ECG, mobility, breathing
- weight
- RR
- patient adherence
- lifestyle & patient history
- quality of life
- resources utilisation
- patients' assessment of C12 system use
- doctors' assessment of C12 system use

# Thank you!



visit us at **www.Commodity12.eu**





**Continuous Multi-parametric and Multi-layered analysis Of DIabetes TYpe 1 & 2**

- Home
- Project Overview
- Project Facts
- Main Objectives
- Expected Outcome
- Presentations & Downloads
- Competencies
- Press Releases
- Contact

Project partners area

Impressum | Privacy



**News...**

COMMODITY12 selected out of 270 proposals to participate in ICT 2013, november 6-8, Vilnius - 30-08-2013  
More than 270 proposals were submitted for the

## Welcome to the Commodity12 Project

### Continuous Multi-parametric and Multi-layered analysis Of DIabetes TYpe 1 & 2

COMMODITY12 aims to design, build, and validate an intelligent system for the analysis of multi-parametric medical data. It will uptake the existing cutting-edge technologies and extend these technologies by combining state-of-the-art networks, software interoperability, and artificial intelligence techniques in order to realize the concept of translational medicine by means of a Personal Health System. Moreover, the COMMODITY12 system will build a new level in patient empowerment, providing the tools for self-management support. Indirectly, this system will also help wider implementation of Personal Health Systems, reinforcing leadership and innovation capability of the European industry in that area.



